Nutra Pharma announces the publication of their study outlining the mechanism of action of their pain drugs to be published in the journal Neuropharmacology.
November 30, 2011 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain. The paper was co-authored by Paul Reid, PhD - the Chief Executive Officer of Nutra Pharma's wholly-owned subsidiary, ReceptoPharm and is available ahead of print on the journal's website or through the link: http://tinyurl.com/painmechanism.
“We are pleased to see continuing publications on the uses of cobra venom and cobra venom components,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “this paper explains one of the proposed mechanisms involved in the relief of pain that we've seen with our venom-based therapeutics, Cobroxin and Nyloxin,” he concluded.
Nutra Pharma currently produces three drugs for the treatment of pain: Cobroxin®, an over-the-counter pain reliever designed to treat moderate to severe (Stage 2) chronic pain; as well as Nyloxin™ and Nyloxin™ Extra Strength, stronger versions of Cobroxin®. These products are currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress.
“Most of the published research conducted on the use of cobra venom as an analgesic took place decades ago,” commented Dr. Paul Reid, CEO of ReceptoPharm. “We have been working diligently to bring the research up to date. While it is well-known that peptides from cobra venom could be used for the treatment of pain and inflammation, the mechanism has not been well-defined. The research in this paper provides a growing understanding of the mechanism of action in pain relief by Alpha-Cobratoxin,” he concluded.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The publication of this article should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.